Choroidal Neovascularization Clinical Trial
Official title:
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
The purpose of this study is to determine the sensitivity of the optical coherence tomography (OCT) test in detecting neovascular AMD in eyes at high risk for CNV development. In order to test this hypothesis, we are conducting a multi-center clinical study at four participating clinical centers. A total of 227 participants will be enrolled. Participants will be followed-up for a period of two years, or until CNV develops in the study eye for which treatment is recommended, to determine the occurrence of CNV. The fundamental design principles of the study are simplicity and parsimony.
Primary Objective:
The purpose of this study is to determine the sensitivity of the OCT in detecting conversion
to neovascular AMD by two years in eyes at high risk for CNV, with FA serving as the gold
standard.
Secondary Objectives:
- To determine the specificity, positive predictive value, and negative predictive value
of the OCT in detecting conversion to neovascular AMD by two years in eyes at high risk
for CNV, with FA serving as the gold standard.
- To compare the sensitivity, specificity, positive predictive value, and negative
predictive value of the OCT to the PHP or the supervised Amsler Grid in subjects who
had either negative PHP and/or negative supervised Amsler grid at baseline for
detection of neovascular AMD by two years in eyes at high risk for CNV
- To describe features of false positives and false negatives with respect to baseline
characteristics seen on PHP testing, supervised Amsler grid testing, and OCT imaging
- To describe the relationship between new visual symptoms experienced by participants
prompting an interim evaluation where treatment for CNV was recommended and findings
seen at the previous study visit (PHP testing, supervised Amsler grid testing, OCT
imaging, other findings on exam, or fluorescein angiography) as well as findings from
the baseline visit
- To determine the physician's detection of CNV development on return study visits
including slit lamp biomicroscopy before viewing ancillary tests from that visit
(supervised Amsler grid, PHP, OCT, fundus photographs, fluorescein angiogram)
All participants will be examined upon enrollment and then followed every three months after
enrollment for two years or until conversion to CNV is positive and treatment is
recommended. Specifically, follow-up visits will occur at 3, 6, 9, 12, 15, 18, 21, and 24
months from the date of the Initial Visit.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
Completed |
NCT02015351 -
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
|
N/A | |
Withdrawn |
NCT01666236 -
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT04075188 -
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
|
N/A | |
Not yet recruiting |
NCT05055973 -
OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.
|
||
Recruiting |
NCT00568191 -
Stratus Versus Cirrus OCT in AMD
|
N/A | |
Completed |
NCT01256632 -
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
|
N/A | |
Recruiting |
NCT00100087 -
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
|
Phase 1/Phase 2 | |
Completed |
NCT04455399 -
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
|
N/A | |
Terminated |
NCT02857894 -
Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)
|
||
Not yet recruiting |
NCT02934841 -
Conbercept in Choroidal Neovascularization Secondary to Uveitis
|
Phase 2 | |
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Completed |
NCT00775411 -
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT00604071 -
Sensitivity of the Home Macular Perimeter (HMP)
|
N/A | |
Completed |
NCT00406250 -
Intravitreal Bevacizumab in Agioid Streaks
|
Phase 1 | |
Withdrawn |
NCT00403156 -
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
|
Phase 1 |